We selected disease endpoints showing association to the GDF15 plasma levels, namely type 2 diabetes, atherosclerosis (excluding cerebral, coronary, and PAD), COPD, psychiatric disorders, and malignant neoplasm of respiratory system and intrathoracic organs (Supplementary file 2d). This evidence concerns the gene GDF15 and peripheral arterial disease.